期刊文献+

K-ras及PTEN在45岁以下妇女子宫内膜癌中的表达 被引量:4

Expression of K-ras and PTEN in endometrial carcinoma under 45-year-old younger women
下载PDF
导出
摘要 目的探讨K-ras及PTEN在45岁以下妇女子宫内膜癌组织中的表达及相关性。方法选取因子宫病变行子宫全切的标本66例,其中子宫内膜腺癌42例、子宫内膜非典型增生6例、正常子宫内膜18例。采用免疫组织化学SP法测定K-ras及PTEN在45岁及以下妇女子宫内膜组织中的表达。结果①K-ras在子宫内膜不典型增生及子宫内膜癌中的表达明显高于正常子宫内膜,差异有显著性(P<0.05);PTEN在正常子宫内膜中、子宫内膜不典型增生和子宫内膜癌中的表达逐渐降低,表达缺失率分别为16.67%、66.67%和85.71%,差异有极显著性(P<0.005)。②K-ras及PTEN在子宫内膜癌中的表达与临床分期、组织学分级、肌层浸润深度及有无淋巴转移无关。③在子宫内膜癌中K-ras与PTEN表达无显著性(rs值=0.187,P>0.05)。K-ras阳性表达与PTEN阳性表达不一致。结论 K-ras及PTEN的异常表达发生在年轻妇女子宫内膜癌的早期,与预后无关。 【Objective】 To study the expressions and relationship among K-ras and PTEN in endometrial carcinoma under 45 of age.【Methods】 Selected 66 cases uterine specimens which were excised for uterine diseases,including 42 cases of endometrial carcinoma,6 cases of atypical endometrial hyperplasia and 18 cases of normal endometrium.The expression of K-ras and PTEN in the tissues of endometrium was detected by the immunohistochemical method.【Results】 The expression of K-ras in atypical endometrial hyperplasia and endometrial carcinoma is much higher than that in normal endometrium(P 0.05).Compared with normal endometrium(16.67%),the negative rates of PTEN in atypical endometrial hyperplasia(66.67%) and endometrial carcinoma(85.71%) increased significantly(P 0.005).The expression of K-ras and PTEN has very little do to with clinical stages,histological grades,myometrial invasion depth and lymphatic metastasis.In endometrial carcinoma group,there was no correlation between the expressions of K-ras and PTEN(rs=0.187,P 0.05).The positive expression of K-ras had inconsistency with PTEN.【Conclusions】 These results suggest that the abnormal expression of K-ras and PTEN might be a valuable index for the diagnosis of endometrial carcinoma in the early stage for the patients under 45 years old.
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2011年第14期1647-1651,共5页 China Journal of Modern Medicine
基金 湖南省教育厅科学研究项目(No:09C036)
关键词 子宫内膜癌 K-RAS PTEN endometrial carcinoma K-ras PTEN
  • 相关文献

参考文献3

二级参考文献22

  • 1连利娟.林巧稚妇科肿瘤学[M]:第3版[M].北京:人民卫生出版社,2001.139.
  • 2Sasaki H, Nishii H, Takahashi H, et al. Mutation of the K-ras protooncogene in human endometrial hyperplasia and carcinoma[J]. Cancer Res, 1993,53: 1906-1910.
  • 3Scambia G, Catozzi L, Benedetti-Panici P, et al. Expression of ras p21 oncoprotein in normal and neoplastic human endometrium[J]. Gynecol Oncol, 1993,50(3):339-346.
  • 4Long CA, Timothy J, Brien O, et al. Ras oncogene in expression in adnoeareinoma of endometrium[J]. Am J Obstet Onco1,1993,49:113.
  • 5Aita V M,Liang X H,Murty V V,et al.Cloning and genomic organization of beclin 1,a candidate tumor suppressor gene on chromosome 17q21[J].Genomic,1999,59 (1):59-65.
  • 6Yue Z,Jin S,Yang C,et al.Beclin1,an autophagy gene essential for early embryonic development,is a haploinsufficient tumor suppressor[J].Proc Natl Acad Sci USA,2003,100(25):15077-15082.
  • 7Qu X,Yu J,Bhagat G,et al.Promotion of tumorigenesis by heterozygous disruption of the Beclin1 autophagy gene[J].J Clin Invest,2003,112(12):1809-1820.
  • 8Maehama T,Dixon J E.The tumor suppressor,PTEN/MMACl,dephosphorytates the lipid second messager phosphatidylionosito 3,4,5-trisphosphate[J].J Biol chem,1998,273 (22):13375-13378.
  • 9Salvesen H B,Stefansson I,Kalvens M B,et al.Loss of PTEN expression is associated with metastatic disease in patients with endometrial carcinoma[J].Cancer,2002,94(6):2185-2191.
  • 10Ogier-Denis E,Codogno P.Autophagy:a barrier or an adaptive response to cancer[J].Biochim Biophys Acta,2003,1603(2):113-128.

共引文献28

同被引文献58

  • 1吴琼燕,万小云,谢幸.子宫内膜样腺癌发生的分子生物学研究现状[J].国外医学(妇幼保健分册),2005,16(6):425-428. 被引量:4
  • 2赵剑虹,万小云,谢幸,周彩云,吴琼燕.Beclin1、PTEN在子宫内膜癌组织中的表达及其意义[J].癌症,2006,25(6):753-757. 被引量:27
  • 3王爱梅,许恪淳,祝明洁,王国斌,姚晓虹.子宫内膜癌p16、p53和C-erbB-2的表达及其临床意义[J].上海交通大学学报(医学版),2007,27(8):993-995. 被引量:15
  • 4Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma [J]. Nature, 2013, 497(7447): 67 -73.
  • 5Mori N, Kyo S, Nakamura M, et al. Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer[J]. Br J Cancer, 2010, 103 (6) : 889 - 898.
  • 6Dobrzycka B, Terlikowski SJ, Mazurek A, et al. Circulating free DNA, p53 antibody and mutations of KRAS gene in endometrial cancer[J]. lnt J Cancer, 2010, 127 (3) : 612 - 621.
  • 7Esteller M, Garcia A, Martlnez-Palones JM, et al. The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer[J]. Eur J Cancer, 1997, 33 (10): 1572 - 1577.
  • 8MUller GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers[J]. J Natl Cancer Inst , 2000, 92 (11) : 924 - 930.
  • 9Zhou C, Bae-Jump VL, Whang YE, et al. The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels [J]. Gynecol Oncol , 2006, 101 (2) : 305 - 310.
  • 10Kataoka M, Okabayashi T, Johira H, et al. Aherration of p53 and DCC in gastric and colorectal cancer[J]. Oncol Rep, 2000, 7 (1) : 99 - 103.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部